Novel functions of RANK(L) signaling in the immune system

Advances in Experimental Medicine and Biology

Volumn 658, Issue , 2010, Pages 77-94

  Leibbrandt, Andreas ^b   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b NONE

Author keywords

Autoimmunity; Immune system; OPG; Osteoclast; Osteoclastogenesis; Osteoimmunology; Osteoporosis; RANK; RANKL; Rheumatoid arthritis

Indexed keywords

DENOSUMAB; LYMPHOTOXIN; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA;

ALBERS SCHOENBERG DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BINDING AFFINITY; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; ENZYME INHIBITION; EPITHELIUM CELL; EXTRAMEDULLARY HEMATOPOIESIS; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; MULTIPLE MYELOMA; NONHUMAN; ORGANOGENESIS; OSTEOCLAST; OSTEOLYSIS; PEYER PATCH; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMOCYTE; THYMUS;

ANIMALS; BONE RESORPTION; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

MUS;

EID: 77953151846     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1050-9_9     Document Type: Conference Paper

References (86)

1. Abu-Amer, Y. (2001). IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest, 107: 1375-1385. (Pubitemid 32522031)
2. Akiyama, T., Shimo, Y., Yanai, H. et al. (2008). The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and selftolerance. Immunity, 29: 423-437.
3. Alimzhanov, M.B., Kuprash, D.V., Kosco-Vilbois, M.H. et al. (1997). Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc Natl Acad Sci U S A, 94: 9302-9307.
4. Anderson, G., Lane, P.J., & Jenkinson, E.J. (2007). Generating intrathymic microenvironments to establish T-cell tolerance. Nat Rev Immunol, 7: 954-963. (Pubitemid 350166055)
5. Anderson, D.M., Maraskovsky, E., Billingsley, W.L. et al. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 390: 175-179. (Pubitemid 27507987)
6. Anderson, M.S., Venanzi, E.S., Klein, L. et al. (2002). Projection of an immunological self shadow within the thymus by the aire protein. Science, 298: 1395-1401. (Pubitemid 35346134)
7. Bachmann, M.F., Wong, B.R., Josien, R. et al. (1999). TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med, 189: 1025-1031. (Pubitemid 29169819)
8. Banchereau, J., & Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature, 392: 245-252. (Pubitemid 28155090)
9. Bendele, A., McComb, J., Gould, T. et al. (1999). Animal models of arthritis: relevance to human disease. Toxicol Pathol, 27: 134-142. (Pubitemid 29075759)
10. Bendixen, A.C., Shevde, N.K., Dienger, K.M. et al. (2001). IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA, 98: 2443-2448 (Pubitemid 32209501)
11. Akiyama, T., Maeda, S., Yamane, S. et al. (2005). Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science, 308: 248-251. (Pubitemid 40558859)
12. Boehm, T., Scheu, S., Pfeffer, K. et al. (2003). Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTbetaR. J Exp Med, 198: 757-769. (Pubitemid 37087775)
13. Body, J.J., Facon, T., Coleman, R.E. et al. (2006). A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res, 12: 1221-1228. (Pubitemid 43342512)
14. Bone, H.G., Bolognese, M.A., Yuen, C.K. et al. (2008). Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab, 93: 2149-2157. (Pubitemid 351831529)
15. Brandt, J., Haibel, H., Cornely, D. et al. (2000). Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum, 43: 1346-1352. (Pubitemid 30416320)
16. Campagnuolo, G., Bolon, B., & Feige, U. (2002). Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum, 46: 1926-1936 (Pubitemid 34774526)
17. Bolon, B., Campagnuolo, G., & Feige, U. (2002). Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci, 59: 1569-1576. (Pubitemid 35239311)
18. Chin, R.K., Lo, J.C., Kim, O. et al. (2003). Lymphotoxin pathway directs thymic Aire expression. Nat Immunol, 4: 1121-1127. (Pubitemid 37428040)
19. Cohen, S.B., Dore, R.K., Lane, N.E. et al. (2008). Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum, 58: 1299-1309. (Pubitemid 351705919)
20. De Togni, P., Goellner, J., Ruddle, N.H. et al. (1994). Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science, 264: 703-707. (Pubitemid 24185880)
21. Dong, C. (2006). Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol, 6: 329-333.
22. Dougall, W.C., & Chaisson, M. (2006). The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev, 25: 541-549. (Pubitemid 46071863)
23. Dougall,W.C., Glaccum, M., Charrier, K. et al. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev, 13: 2412-2424. (Pubitemid 29453612)
24. Ebeling, P.R., Erbas, B., Hopper, J.L. et al. (1998). Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res, 13: 1283-1289. (Pubitemid 28373330)
25. Emery, J.G., McDonnell, P., Burke, M.B. et al. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 273: 14363-14367. (Pubitemid 28319153)
26. Fata, J.E., Kong, Y.Y., Li, J. et al. (2000). The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell, 103: 41-50.
27. Feldmann, M., Brennan, F.M., & Maini, R.N. (1996). Rheumatoid arthritis. Cell, 85: 307-310. (Pubitemid 26160702)
28. Feldmann, M., Brennan, F.M., & Maini, R.N. (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol, 14: 397-440. (Pubitemid 26130190)
29. Futterer, A., Mink, K., Luz, A. et al. (1998). The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity, 9: 59-70. (Pubitemid 28361295)
30. Fu, Y.X., Chaplin, D.D. (1999). Development and maturation of secondary lymphoid tissues. Annu Rev Immunol, 17: 399-433. (Pubitemid 29241130)
31. Green, E.A., Choi, Y., & Flavell, R.A. (2002). Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCERANK signals. Immunity, 16: 183-191. (Pubitemid 34211959)
32. Green, E.A., & Flavell, R.A. (2000). The temporal importance of TNFalpha expression in the development of diabetes. Immunity, 12: 459-469.
33. Harrington, L.E., Hatton, R.D., Mangan, P.R. et al. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6: 1123-1132. (Pubitemid 41541790)
34. Hikosaka, Y., Nitta, T., Ohigashi, I. et al. (2008). The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity, 29: 438-450.
35. Hofbauer, L.C., Khosla, S., Dunstan, C.R. et al. (1999). Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 140: 4367-4370. (Pubitemid 30647136)
36. Horwood, N.J., Elliott, J., Martin, T.J. et al. (2001). IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol, 166: 4915-4921. (Pubitemid 32280701)
37. Hsu, H., Lacey, D.L., Dunstan, C.R. et al. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A, 96: 3540-3545. (Pubitemid 29168945)
38. Ingulli, E., Mondino, A., Khoruts, A. et al. (1997). In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med, 185: 2133-2141 (Pubitemid 27265997)
39. Irla, M., Hugues, S., Gill, J. et al. (2008). Autoantigen-specific interactions with CD4+ thymocytes control mature medullary thymic epithelial cell cellularity. Immunity, 29: 451-463.
40. Josien, R., Li, H.L., Ingulli, E. et al. (2000). TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med, 191: 495-502.
41. Josien, R., Wong, B.R., Li, H.L. et al. (1999). TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol, 162: 2562-2568. (Pubitemid 29309274)
42. Kanematsu, M., Sato, T., Takai, H., et al. (2000). Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res, 15: 1321-1329. (Pubitemid 30413864)
43. Keffer, J., Probert, L., Cazlaris, H. et al (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J, 10: 4025-4031 (Pubitemid 21905432)
44. Kim, D., Mebius, R.E., MacMicking, J.D. et al. (2000). Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med, 192: 1467-1478.
45. Kong, Y.Y., Feige, U., Sarosi, I. et al. (1999). Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 42: 304-309.
46. Kong, Y.Y., Yoshida, H., Sarosi, I. et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397: 315-323.
47. Koni, P.A., Sacca, R., Lawton, P. et al. (1997). Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity, 6: 491-500. (Pubitemid 27208204)
48. Korganow, A.S., Ji, H., Mangialaio, S. et al. (1999). From systemic T cell selfreactivity to organ-specific autoimmune disease via immunoglobulins. Immunity, 10: 451-461. (Pubitemid 29205481)
49. Kotake, S., Udagawa, N., Hakoda, M. et al. (2001). Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum, 44: 1003-1012. (Pubitemid 32433604)
50. Kotake, S., Udagawa, N., Takahashi, N. et al. (1999). IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest, 103: 1345-1352. (Pubitemid 29218305)
51. Kouskoff, V., Korganow, A.S., Duchatelle, V., &et al. (1996). Organ-specific disease provoked by systemic autoimmunity. Cell, 87: 811-822. (Pubitemid 26404281)
52. Kyewski, B., & Klein, L. (2006). A central role for central tolerance. Annu Rev Immunol, 24: 571-606.
53. Lacey, D.L., Timms, E., Tan, H.L. et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165-176. (Pubitemid 28180851)
54. Li, J., Sarosi, I., Yan, X.Q. et al. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A, 97: 1566-1571. (Pubitemid 30118482)
55. Lipton, A. (2006). Future treatment of bone metastases. Clin Cancer Res, 12: 6305s-6308s. (Pubitemid 44703808)
56. Lipton, A., Steger, G.G., Figueroa, J. et al. (2007). Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol, 25: 4431-4437. (Pubitemid 350013849)
57. Loser, K.,Mehling, A., Loeser, S. et al. (2006). Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med, 12: 1372-1379. (Pubitemid 44924495)
58. Mahamed, D.A., Marleau, A., Alnaeeli, M. et al. (2005). G(-) anaerobes-reactive CD4+ Tcells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes, 54: 1477-1486. (Pubitemid 40586680)
59. Manoury-Schwartz, B., Chiocchia, G., Bessis, N. et al. (1997). High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol, 158: 5501-5506. (Pubitemid 127681259)
60. Matsumoto, M., Mariathasan, S., Nahm, M.H. et al. (1996). Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science, 271: 1289-1291. (Pubitemid 26082651)
61. Mebius, R.E. (2003). Organogenesis of lymphoid tissues. Nat Rev Immunol, 3: 292-303. (Pubitemid 37328682)
62. Mebius, R.E., Rennert, P., & Weissman, I.L. (1997). Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity, 7: 493-504. (Pubitemid 27508701)
63. Mehling, A., Loser, K., Varga, G. et al. (2001). Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med, 194: 615-628. (Pubitemid 32844772)
64. McClung, M.R., Lewiecki, E.M., Cohen, S.B. et al. (2006). Denosumab in postmenopausal women with low bone mineral density. N Engl J Med, 354: 821-831. (Pubitemid 43290920)
65. Mori, H., Kitazawa, R., Mizuki, S. et al. (2002). RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol, 117: 283-292. (Pubitemid 34253333)
66. Muller-Ladner, U., Gay, R.E., & Gay, S. (1998). Molecular biology of cartilage and bone destruction. Curr Opin Rheumatol, 10: 212-219. (Pubitemid 28286811)
67. Nakashima, T., Wada, T., & Penninger, J.M. (2003). RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol, 15: 280-287. (Pubitemid 36532608)
68. Oliveri, M.B., Mautalen, C.A., Rodriguez Fuchs, C.A. et al. (1991). Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J, 39: 45-48.
69. Oxenius, A., Campbell, K.A., Maliszewski, C.R. et al. (1996). CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med, 183: 2209-2218. (Pubitemid 26158912)
70. Oliveri, MB., Mautalen, C.A., Rodriguez Fuchs, C.A. et al. (1991). Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J, 39: 45-48.
71. Oxenius, A., Campbell, K.A., Maliszewski, C.R. et al. (1996). CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med, 183: 2209-2218. (Pubitemid 26158912)
72. Panayi, G.S., Lanchbury, J.S., & Kingsley, G.H. (1992). The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum, 35: 729-735.
73. Park, H., Li, Z., Yang, X.O. et al. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6: 1133-1141. (Pubitemid 41541791)
74. Pettit, A.R., Ji, H., von Stechow, D. et al. (2001). TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol, 159: 1689-1699. (Pubitemid 33062512)
75. Piepkorn, B., Kann, P., Forst, T. et al. (1997). Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res, 29: 584-591. (Pubitemid 28053672)
76. Quezada, S.A., Jarvinen, L.Z., Lind, E.F. et al. (2004). CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol, 22: 307-328. (Pubitemid 38680425)
77. Redlich, K., Hayer, S., Maier, A. et al. (2002). Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum, 46: 785-792. (Pubitemid 34214261)
78. Rennert, P.D., Browning, J.L., & Hochman, P.S. (1997). Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization. Int Immunol, 9: 1627-1639. (Pubitemid 27494126)
79. Rennert, P.D., James, D., Mackay, F. et al. (1998). Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity, 9: 71-79. (Pubitemid 28361296)
80. Romas, E., Sims, N.A., Hards, D.K. et al. (2002). Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol, 161: 1419-1427.
81. Rossi, S.W., Jenkinson, W.E., Anderson, G. et al. (2006). Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature, 441: 988-991. (Pubitemid 43980353)
82. Rossi, S.W., Kim, M.Y., Leibbrandt, A. et al. (2007). RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med, 204: 1267-1272. (Pubitemid 46919863)
83. Roy, M., Waldschmidt, T., Aruffo, A. et al. (1993). The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol, 151: 2497-2510. (Pubitemid 23264502)
84. Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol, 6: 345-352. (Pubitemid 41716771)
85. Sato, K., Suematsu, A., Okamoto, K. et al. (2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med, 203: 2673-2682. (Pubitemid 44833343)
86. Seitz, M., & Hunstein, W. (1985). Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. Ann Rheum Dis, 44: 438-445. (Pubitemid 15071689)